Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Calaspargase pegol-mknl + Cytarabine + Idarubicin|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Calaspargase pegol-mknl||Asparlas||CALASP|EZN-2285EZN 2285|EZN2285|SC-PEG E. coli L-asparaginase||Asparlas (calaspargase pegol-mknl) is a pegylated version of L-asparaginase derived from E.coli, which converts L-asparagine to ammonia and L-aspartic acid, potentially resulting in reduced levels of asparagine leading to inhibition of protein synthesis and tumor cell proliferation, and increased cell death (NCI Drug Dictionary). Asparlas (calaspargase pegol-mknl) is approved as a component of multi-agent chemotherapy in acute lymphoblastic leukemia (FDA.gov).|
|Cytarabine||Cytosar-U||Ara-C||Cytosar-U (cytarabine) is a cytidine analog that, when incorporated into DNA, inhibits DNA synthesis and repair (PMID: 32524309).|
|Idarubicin||Idamycin||Idarubicin Hcl||Chemotherapy - Anthracycline 13||Idarubicin is an anthracycline, which inhibits DNA replication thereby preventing RNA and protein synthesis and, in combination with other approved drugs, is FDA approved for acute myelogenous leukemia (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04953780||Phase I||Calaspargase pegol-mknl + Cytarabine + Idarubicin||2157GCCC:Phase 1 of Calaspargase Pegol-mknl w/ Cytarabine and Idarubicin in Newly Dx AML||Recruiting||USA||0|